Carlsmed, INC Form 4 insider transactions

Carlsmed CEO Michael Cordonnier executed a cashless exercise of stock options and sold shares to cover costs, while also exercising additional options.

Carlsmed, Inc.'s Chief Commercial Officer, William Scott Durall, was granted 44,977 restricted stock units, vesting over three years.

Carlsmed's Chief IP Officer and Director, Niall Casey, acquired 44,977 restricted stock units, increasing his beneficial ownership to 982,562 shares.

CARLSMED, Inc. CEO and President Michael Cordonnier was granted 117,316 restricted stock units, vesting over three years.

CARLSMED, Inc.'s CFO and Treasurer, Leonard M. Greenstein, acquired 44,977 shares of common stock through a restricted stock unit grant.

B Capital Group Management and its affiliated funds significantly increased their beneficial ownership in Carlmed, Inc. to over 8.3 million common shares following automatic conversions of preferred stock and a direct purchase at the company's initial public offering.

Presidio Management Group XII and affiliated entities converted 5,642,073 shares of CARLSMED, Inc. preferred stock into common stock, signaling a significant step towards the company's anticipated initial public offering.

Carlsmed, Inc.'s Chief Commercial Officer, William Scott Durall, was granted 71,429 stock options with a $15 exercise price, vesting quarterly over four years.

CARLSMED, Inc. CEO and President Michael Cordonnier reported the acquisition of 142,857 stock options and the conversion of 3,612 shares of Series B Preferred Stock into common stock.

CARLSMED Director Kevin Sidow reported significant changes in his beneficial ownership, including an RSU grant, preferred stock conversion, and a direct purchase of common stock during the company's initial public offering.

Carlsmed Director Robert Mittendorff II reported the conversion of millions of preferred shares into common stock and the purchase of over 1.3 million common shares at $15, increasing his indirect beneficial ownership to over 8.3 million shares following the company's initial public offering.

Carlsmed, Inc. Director Kevin C. O'Boyle received an award of 17,333 restricted stock units, which will vest in equal annual installments over three years.

Carlsmed, Inc.'s CFO and Treasurer, Leonard M. Greenstein, was granted 71,429 stock options with a $15 exercise price, vesting quarterly over four years.

CARLSMED, Inc.'s Chief IP Officer and Director, Niall Casey, reported the acquisition of 3,612 common shares through preferred stock conversion and a grant of 53,571 stock options.

Carlsmed Director Jonathan Root increased his direct and indirect holdings in the company through a significant purchase in the initial public offering and the conversion of preferred stock, alongside an award of restricted stock units.

CARLSMED Director Philip M. Young reported significant acquisitions of company stock, including purchases in the initial public offering and an award of restricted stock units.